false
0001971532
0001971532
2025-10-22
2025-10-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October
22, 2025
TELOMIR
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Florida |
|
001-41952 |
|
87-2606031 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
100
SE 2nd St, Suite
2000, #1009
Miami,
Florida 33131
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (786)
396-6723
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| |
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, no par value |
|
TELO |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events
Telomir
Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’s “Kill-and-Clean” Defense Systems in an Aggressive
Prostate Cancer Model, Outperforming Rapamycin and Chemo
New
findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell-death and glutathione-based detoxification
pathways often disrupted in cancer.
On
October 22, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) reported new preclinical data from an aggressive prostate-cancer
model evaluating its investigational compound Telomir-1.
The
study focused on DNA methylation, an epigenetic process that influences whether genes are active or silenced, and assessed two
additional defense genes central to cancer biology:
CASP8,
which regulates apoptosis (programmed cell death), and GSTP1, which encodes glutathione S-transferase Pi 1 — a key enzyme
in the body’s detoxification system that uses glutathione to neutralize oxidative and chemical stress and help maintain
cellular balance.
Apoptosis
(“kill”) and detoxification (“clean”) pathways are two of the body’s fundamental defense systems against
cancer initiation and progression. The Company believes that modulation of these pathways through DNA-methylation control may represent
an important area of ongoing scientific evaluation for Telomir-1 and related oncology research programs.
The
study was conducted in mice bearing human aggressive prostate cancer tumor and were treated daily with oral Telomir-1 or reference compounds.
On Day 21 of the study, Telomir-1 treatment was associated with reduced DNA methylation of both CASP8 and GSTP1 relative to vehicle and
chemotherapy groups, suggesting potential re-activation of apoptosis and detoxification-related gene functions. Chemotherapy alone did
not appear to reduce methylation of both genes, while the combination of Telomir-1 and chemotherapy showed lower DNA methylation levels
than chemotherapy alone, indicating that combined therapy with Telomir-1 may potentiate chemotherapy related epigenetic effects in this
model.
At
earlier time points (Day 10), the mTOR pathway inhibitor Rapamycin was associated with an initial reduction in methylation for
both genes, consistent with indirect effects on cellular metabolism and oxidative stress. By Day 21, the Rapamycin related effect had
partially rebounded, whereas Telomir-1 continued to show a progressive and more sustained decrease in DNA methylation. The Company believes
these data help differentiate Telomir-1’s epigenetic activity from the effects of Rapamycin and underscore Telomir-1’s potential
relevance to oncology research.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
TELOMIR
PHARMACEUTICALS, INC. |
| |
|
| Dated:
October 22, 2025 |
By: |
/s/
Erez Aminov |
| |
Name:
|
Erez
Aminov |
| |
Title: |
Chief
Executive Officer |
